Press Releases

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools.

Jan 08, 2020
- AGEN1223 is a novel bi-specific designed to selectively deplete regulatory T cells in the tumor microenvironment - First patient dosed; combinations with other IO agents planned for 2020 LEXINGTON, Mass., Jan. 8, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with
Nov 12, 2019
LEXINGTON, Mass., Nov. 12, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1  and cancer vaccines, announced that it will host an R&D Day on November 15, 2019.
Nov 04, 2019
- PD-1 plus CTLA-4 cervical trial completes planned accrual & planned interim analysis - PD-1 cervical trial on track to complete accrual & planned interim analysis by year-end - Four novel I-O antibodies clear INDs & advance into clinical trials - NexGen CTLA-4 (AGEN1181) advances to 3rd cohort;
Aug 28, 2019
FDA acceptance of IND filing for AGEN1223; triggers cash milestone AGEN1223 is a first-in-class bi-specific designed to deplete regulatory T cells in tumor microenvironment LEXINGTON, Mass., August 28, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a
Aug 21, 2019
Invented by Agenus, licensed to Gilead, GS-1423 is a bi-functional antibody designed to block tumor escape mechanisms Supply supports ongoing Phase 1 of GS-1423 in patients with advanced solid tumors LEXINGTON, Mass., August 21, 2019 / PRNewswire / -- Agenus Inc.
Aug 08, 2019
- FDA acceptance of IND filing for AGEN2373 triggers payment and clears path to begin clinical trials - The payment represents the second milestone in Gilead partnership achieved in 2019 LEXINGTON, Mass., Aug. 8, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O)